nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—CYP1A2—Pentoxifylline—systemic scleroderma	0.0908	0.297	CbGbCtD
Epinephrine—CYP1A2—Leflunomide—systemic scleroderma	0.0866	0.283	CbGbCtD
Epinephrine—CYP2C9—Leflunomide—systemic scleroderma	0.078	0.255	CbGbCtD
Epinephrine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.028	0.0917	CbGbCtD
Epinephrine—CYP3A4—Prednisone—systemic scleroderma	0.0224	0.0733	CbGbCtD
Epinephrine—CYP2C9—cardial valve—systemic scleroderma	0.0158	0.385	CbGeAlD
Epinephrine—Contusion—Mometasone—systemic scleroderma	0.00592	0.0126	CcSEcCtD
Epinephrine—Nephropathy—Mycophenolate mofetil—systemic scleroderma	0.00591	0.0126	CcSEcCtD
Epinephrine—Necrosis—Captopril—systemic scleroderma	0.00578	0.0123	CcSEcCtD
Epinephrine—Pallor—Captopril—systemic scleroderma	0.00547	0.0116	CcSEcCtD
Epinephrine—Supraventricular tachycardia—Mycophenolic acid—systemic scleroderma	0.00544	0.0116	CcSEcCtD
Epinephrine—Lightheadedness—Pentoxifylline—systemic scleroderma	0.00535	0.0114	CcSEcCtD
Epinephrine—Drug interaction—Captopril—systemic scleroderma	0.00489	0.0104	CcSEcCtD
Epinephrine—Tingling sensation—Leflunomide—systemic scleroderma	0.00465	0.00987	CcSEcCtD
Epinephrine—Skin necrosis—Methotrexate—systemic scleroderma	0.00456	0.00969	CcSEcCtD
Epinephrine—Blood pressure increased—Captopril—systemic scleroderma	0.00453	0.00963	CcSEcCtD
Epinephrine—Pallor—Leflunomide—systemic scleroderma	0.00451	0.00957	CcSEcCtD
Epinephrine—Pallor—Mycophenolic acid—systemic scleroderma	0.0043	0.00913	CcSEcCtD
Epinephrine—Supraventricular tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00429	0.00912	CcSEcCtD
Epinephrine—Contusion—Leflunomide—systemic scleroderma	0.00428	0.0091	CcSEcCtD
Epinephrine—Ventricular fibrillation—Lisinopril—systemic scleroderma	0.00419	0.00891	CcSEcCtD
Epinephrine—Memory impairment—Lisinopril—systemic scleroderma	0.00409	0.00869	CcSEcCtD
Epinephrine—Contusion—Mycophenolic acid—systemic scleroderma	0.00409	0.00868	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Mycophenolic acid—systemic scleroderma	0.00395	0.00838	CcSEcCtD
Epinephrine—Rales—Methotrexate—systemic scleroderma	0.00389	0.00825	CcSEcCtD
Epinephrine—Blood pressure increased—Leflunomide—systemic scleroderma	0.00374	0.00794	CcSEcCtD
Epinephrine—ADRB3—connective tissue—systemic scleroderma	0.00373	0.0908	CbGeAlD
Epinephrine—Blood pressure increased—Mycophenolic acid—systemic scleroderma	0.00357	0.00757	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Lisinopril—systemic scleroderma	0.00356	0.00755	CcSEcCtD
Epinephrine—Drug interaction—Lisinopril—systemic scleroderma	0.00346	0.00735	CcSEcCtD
Epinephrine—Pallor—Mycophenolate mofetil—systemic scleroderma	0.00339	0.00721	CcSEcCtD
Epinephrine—Cerebrovascular accident—Captopril—systemic scleroderma	0.00336	0.00713	CcSEcCtD
Epinephrine—Nephropathy—Methotrexate—systemic scleroderma	0.00335	0.00711	CcSEcCtD
Epinephrine—Drowsiness—Pentoxifylline—systemic scleroderma	0.00335	0.00711	CcSEcCtD
Epinephrine—ADRBK1—smooth muscle tissue—systemic scleroderma	0.00334	0.0812	CbGeAlD
Epinephrine—Sweating—Pentoxifylline—systemic scleroderma	0.00321	0.00681	CcSEcCtD
Epinephrine—Pulmonary oedema—Mycophenolic acid—systemic scleroderma	0.00317	0.00674	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Mycophenolate mofetil—systemic scleroderma	0.00311	0.00662	CcSEcCtD
Epinephrine—Haemoglobin—Pentoxifylline—systemic scleroderma	0.00302	0.00641	CcSEcCtD
Epinephrine—Haemorrhage—Pentoxifylline—systemic scleroderma	0.003	0.00638	CcSEcCtD
Epinephrine—Lightheadedness—Lisinopril—systemic scleroderma	0.00287	0.0061	CcSEcCtD
Epinephrine—Pulmonary oedema—Lisinopril—systemic scleroderma	0.00286	0.00607	CcSEcCtD
Epinephrine—Flushing—Pentoxifylline—systemic scleroderma	0.00279	0.00592	CcSEcCtD
Epinephrine—Renal impairment—Mycophenolic acid—systemic scleroderma	0.00272	0.00578	CcSEcCtD
Epinephrine—Arrhythmia—Pentoxifylline—systemic scleroderma	0.00268	0.0057	CcSEcCtD
Epinephrine—Hypoglycaemia—Mycophenolic acid—systemic scleroderma	0.00265	0.00563	CcSEcCtD
Epinephrine—ADRBK1—digestive system—systemic scleroderma	0.00264	0.0641	CbGeAlD
Epinephrine—Erythema—Pentoxifylline—systemic scleroderma	0.00262	0.00555	CcSEcCtD
Epinephrine—Tension—Pentoxifylline—systemic scleroderma	0.00257	0.00545	CcSEcCtD
Epinephrine—Nervousness—Pentoxifylline—systemic scleroderma	0.00254	0.0054	CcSEcCtD
Epinephrine—Psychotic disorder—Mycophenolic acid—systemic scleroderma	0.00253	0.00537	CcSEcCtD
Epinephrine—Pulmonary oedema—Mycophenolate mofetil—systemic scleroderma	0.0025	0.00532	CcSEcCtD
Epinephrine—Renal failure—Captopril—systemic scleroderma	0.00249	0.0053	CcSEcCtD
Epinephrine—Hypokalaemia—Leflunomide—systemic scleroderma	0.00247	0.00524	CcSEcCtD
Epinephrine—Renal impairment—Lisinopril—systemic scleroderma	0.00245	0.0052	CcSEcCtD
Epinephrine—Memory impairment—Prednisone—systemic scleroderma	0.00243	0.00516	CcSEcCtD
Epinephrine—Necrosis—Prednisone—systemic scleroderma	0.00243	0.00516	CcSEcCtD
Epinephrine—Agitation—Pentoxifylline—systemic scleroderma	0.0024	0.0051	CcSEcCtD
Epinephrine—Hypoglycaemia—Lisinopril—systemic scleroderma	0.00239	0.00507	CcSEcCtD
Epinephrine—Cerebrovascular accident—Lisinopril—systemic scleroderma	0.00238	0.00505	CcSEcCtD
Epinephrine—Hypokalaemia—Mycophenolic acid—systemic scleroderma	0.00236	0.005	CcSEcCtD
Epinephrine—Palpitations—Pentoxifylline—systemic scleroderma	0.00231	0.00491	CcSEcCtD
Epinephrine—Sweating increased—Leflunomide—systemic scleroderma	0.00228	0.00485	CcSEcCtD
Epinephrine—Hallucination—Captopril—systemic scleroderma	0.00227	0.00481	CcSEcCtD
Epinephrine—Hypertension—Pentoxifylline—systemic scleroderma	0.00226	0.0048	CcSEcCtD
Epinephrine—Chest pain—Pentoxifylline—systemic scleroderma	0.00223	0.00473	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.00221	0.0047	CcSEcCtD
Epinephrine—ADRBK1—lung—systemic scleroderma	0.0022	0.0535	CbGeAlD
Epinephrine—Contusion—Prednisone—systemic scleroderma	0.00219	0.00464	CcSEcCtD
Epinephrine—Renal impairment—Mycophenolate mofetil—systemic scleroderma	0.00215	0.00456	CcSEcCtD
Epinephrine—Hyperglycaemia—Leflunomide—systemic scleroderma	0.00211	0.00449	CcSEcCtD
Epinephrine—Flushing—Captopril—systemic scleroderma	0.00211	0.00449	CcSEcCtD
Epinephrine—Hypoglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00209	0.00444	CcSEcCtD
Epinephrine—Cerebrovascular accident—Mycophenolate mofetil—systemic scleroderma	0.00208	0.00443	CcSEcCtD
Epinephrine—Tachycardia—Pentoxifylline—systemic scleroderma	0.00208	0.00442	CcSEcCtD
Epinephrine—Skin disorder—Pentoxifylline—systemic scleroderma	0.00207	0.0044	CcSEcCtD
Epinephrine—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.00206	0.00438	CcSEcCtD
Epinephrine—Renal failure—Leflunomide—systemic scleroderma	0.00205	0.00436	CcSEcCtD
Epinephrine—Necrosis—Methotrexate—systemic scleroderma	0.00203	0.00431	CcSEcCtD
Epinephrine—Hyperglycaemia—Mycophenolic acid—systemic scleroderma	0.00202	0.00429	CcSEcCtD
Epinephrine—Haemoglobin—Azathioprine—systemic scleroderma	0.002	0.00424	CcSEcCtD
Epinephrine—Psychotic disorder—Mycophenolate mofetil—systemic scleroderma	0.00199	0.00424	CcSEcCtD
Epinephrine—Haemorrhage—Azathioprine—systemic scleroderma	0.00199	0.00422	CcSEcCtD
Epinephrine—Sweating increased—Lisinopril—systemic scleroderma	0.00196	0.00417	CcSEcCtD
Epinephrine—Renal failure—Mycophenolic acid—systemic scleroderma	0.00196	0.00416	CcSEcCtD
Epinephrine—Tension—Captopril—systemic scleroderma	0.00195	0.00413	CcSEcCtD
Epinephrine—Insomnia—Pentoxifylline—systemic scleroderma	0.00193	0.0041	CcSEcCtD
Epinephrine—Nervousness—Captopril—systemic scleroderma	0.00193	0.00409	CcSEcCtD
Epinephrine—Chest pain—Mometasone—systemic scleroderma	0.00192	0.00408	CcSEcCtD
Epinephrine—Sweating—Mycophenolic acid—systemic scleroderma	0.00191	0.00406	CcSEcCtD
Epinephrine—Somnolence—Pentoxifylline—systemic scleroderma	0.0019	0.00403	CcSEcCtD
Epinephrine—Haemoglobin—Leflunomide—systemic scleroderma	0.00189	0.00401	CcSEcCtD
Epinephrine—Haemorrhage—Leflunomide—systemic scleroderma	0.00188	0.00399	CcSEcCtD
Epinephrine—Hypokalaemia—Mycophenolate mofetil—systemic scleroderma	0.00186	0.00395	CcSEcCtD
Epinephrine—Extravasation—Methotrexate—systemic scleroderma	0.00183	0.00388	CcSEcCtD
Epinephrine—Skin exfoliation—Prednisone—systemic scleroderma	0.00182	0.00387	CcSEcCtD
Epinephrine—Hyperglycaemia—Lisinopril—systemic scleroderma	0.00182	0.00386	CcSEcCtD
Epinephrine—Haemoglobin—Mycophenolic acid—systemic scleroderma	0.0018	0.00382	CcSEcCtD
Epinephrine—Haemorrhage—Mycophenolic acid—systemic scleroderma	0.00179	0.0038	CcSEcCtD
Epinephrine—Hallucination—Mycophenolic acid—systemic scleroderma	0.00178	0.00378	CcSEcCtD
Epinephrine—Hypoaesthesia—Mycophenolic acid—systemic scleroderma	0.00178	0.00378	CcSEcCtD
Epinephrine—Arrhythmia—Azathioprine—systemic scleroderma	0.00178	0.00377	CcSEcCtD
Epinephrine—Acute coronary syndrome—Lisinopril—systemic scleroderma	0.00177	0.00376	CcSEcCtD
Epinephrine—Renal failure—Lisinopril—systemic scleroderma	0.00177	0.00375	CcSEcCtD
Epinephrine—Myocardial infarction—Lisinopril—systemic scleroderma	0.00176	0.00374	CcSEcCtD
Epinephrine—Palpitations—Captopril—systemic scleroderma	0.00175	0.00372	CcSEcCtD
Epinephrine—Sweating—Lisinopril—systemic scleroderma	0.00172	0.00366	CcSEcCtD
Epinephrine—Pulmonary oedema—Prednisone—systemic scleroderma	0.0017	0.00361	CcSEcCtD
Epinephrine—Chest pain—Captopril—systemic scleroderma	0.00169	0.00358	CcSEcCtD
Epinephrine—Arrhythmia—Leflunomide—systemic scleroderma	0.00168	0.00356	CcSEcCtD
Epinephrine—Paraesthesia—Mometasone—systemic scleroderma	0.00165	0.00351	CcSEcCtD
Epinephrine—Mental disorder—Leflunomide—systemic scleroderma	0.00164	0.00349	CcSEcCtD
Epinephrine—SLC22A2—digestive system—systemic scleroderma	0.00162	0.0394	CbGeAlD
Epinephrine—Hallucination—Lisinopril—systemic scleroderma	0.0016	0.00341	CcSEcCtD
Epinephrine—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.0016	0.0034	CcSEcCtD
Epinephrine—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00159	0.00338	CcSEcCtD
Epinephrine—Tachycardia—Captopril—systemic scleroderma	0.00158	0.00335	CcSEcCtD
Epinephrine—Mental disorder—Mycophenolic acid—systemic scleroderma	0.00157	0.00333	CcSEcCtD
Epinephrine—Acute coronary syndrome—Mycophenolate mofetil—systemic scleroderma	0.00155	0.0033	CcSEcCtD
Epinephrine—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.00155	0.00329	CcSEcCtD
Epinephrine—Myocardial infarction—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00328	CcSEcCtD
Epinephrine—Tension—Mycophenolic acid—systemic scleroderma	0.00153	0.00325	CcSEcCtD
Epinephrine—ADRB1—connective tissue—systemic scleroderma	0.00153	0.0371	CbGeAlD
Epinephrine—Skin exfoliation—Methotrexate—systemic scleroderma	0.00152	0.00323	CcSEcCtD
Epinephrine—Nervousness—Mycophenolic acid—systemic scleroderma	0.00151	0.00321	CcSEcCtD
Epinephrine—Sweating—Mycophenolate mofetil—systemic scleroderma	0.00151	0.0032	CcSEcCtD
Epinephrine—Flushing—Lisinopril—systemic scleroderma	0.0015	0.00318	CcSEcCtD
Epinephrine—Insomnia—Captopril—systemic scleroderma	0.00146	0.00311	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00146	0.00311	CcSEcCtD
Epinephrine—Paraesthesia—Captopril—systemic scleroderma	0.00145	0.00309	CcSEcCtD
Epinephrine—Palpitations—Leflunomide—systemic scleroderma	0.00144	0.00307	CcSEcCtD
Epinephrine—Arrhythmia—Lisinopril—systemic scleroderma	0.00144	0.00306	CcSEcCtD
Epinephrine—Somnolence—Captopril—systemic scleroderma	0.00144	0.00305	CcSEcCtD
Epinephrine—Agitation—Mycophenolic acid—systemic scleroderma	0.00143	0.00304	CcSEcCtD
Epinephrine—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00302	CcSEcCtD
Epinephrine—Pulmonary oedema—Methotrexate—systemic scleroderma	0.00142	0.00301	CcSEcCtD
Epinephrine—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.00141	0.003	CcSEcCtD
Epinephrine—Mental disorder—Lisinopril—systemic scleroderma	0.00141	0.003	CcSEcCtD
Epinephrine—Dizziness—Pentoxifylline—systemic scleroderma	0.00141	0.003	CcSEcCtD
Epinephrine—Hypertension—Leflunomide—systemic scleroderma	0.00141	0.003	CcSEcCtD
Epinephrine—Hypoaesthesia—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00299	CcSEcCtD
Epinephrine—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00299	CcSEcCtD
Epinephrine—Erythema—Lisinopril—systemic scleroderma	0.0014	0.00298	CcSEcCtD
Epinephrine—Chest pain—Leflunomide—systemic scleroderma	0.00139	0.00295	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00138	0.00293	CcSEcCtD
Epinephrine—Tension—Lisinopril—systemic scleroderma	0.00138	0.00293	CcSEcCtD
Epinephrine—Palpitations—Mycophenolic acid—systemic scleroderma	0.00138	0.00293	CcSEcCtD
Epinephrine—Skin disorder—Azathioprine—systemic scleroderma	0.00137	0.00291	CcSEcCtD
Epinephrine—Nervousness—Lisinopril—systemic scleroderma	0.00136	0.0029	CcSEcCtD
Epinephrine—Vomiting—Pentoxifylline—systemic scleroderma	0.00136	0.00288	CcSEcCtD
Epinephrine—Psychotic disorder—Prednisone—systemic scleroderma	0.00135	0.00287	CcSEcCtD
Epinephrine—Hypertension—Mycophenolic acid—systemic scleroderma	0.00135	0.00286	CcSEcCtD
Epinephrine—Chest pain—Mycophenolic acid—systemic scleroderma	0.00133	0.00282	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00132	0.0028	CcSEcCtD
Epinephrine—Nervous system disorder—Leflunomide—systemic scleroderma	0.00131	0.00278	CcSEcCtD
Epinephrine—Tachycardia—Leflunomide—systemic scleroderma	0.0013	0.00276	CcSEcCtD
Epinephrine—Skin disorder—Leflunomide—systemic scleroderma	0.0013	0.00275	CcSEcCtD
Epinephrine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00129	0.00274	CcSEcCtD
Epinephrine—Nausea—Pentoxifylline—systemic scleroderma	0.00127	0.00269	CcSEcCtD
Epinephrine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00268	CcSEcCtD
Epinephrine—Hypokalaemia—Prednisone—systemic scleroderma	0.00126	0.00268	CcSEcCtD
Epinephrine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00125	0.00265	CcSEcCtD
Epinephrine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00124	0.00264	CcSEcCtD
Epinephrine—Palpitations—Lisinopril—systemic scleroderma	0.00124	0.00263	CcSEcCtD
Epinephrine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00263	CcSEcCtD
Epinephrine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00124	0.00262	CcSEcCtD
Epinephrine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00123	0.00261	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00122	0.00259	CcSEcCtD
Epinephrine—Tension—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00256	CcSEcCtD
Epinephrine—Insomnia—Leflunomide—systemic scleroderma	0.00121	0.00256	CcSEcCtD
Epinephrine—Paraesthesia—Leflunomide—systemic scleroderma	0.0012	0.00254	CcSEcCtD
Epinephrine—Chest pain—Lisinopril—systemic scleroderma	0.0012	0.00254	CcSEcCtD
Epinephrine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00254	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00119	0.00252	CcSEcCtD
Epinephrine—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00118	0.00251	CcSEcCtD
Epinephrine—Vomiting—Mometasone—systemic scleroderma	0.00117	0.00249	CcSEcCtD
Epinephrine—Sweating increased—Prednisone—systemic scleroderma	0.00117	0.00248	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00115	0.00244	CcSEcCtD
Epinephrine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00115	0.00244	CcSEcCtD
Epinephrine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00114	0.00243	CcSEcCtD
Epinephrine—Somnolence—Mycophenolic acid—systemic scleroderma	0.00113	0.0024	CcSEcCtD
Epinephrine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00113	0.0024	CcSEcCtD
Epinephrine—Tachycardia—Lisinopril—systemic scleroderma	0.00112	0.00237	CcSEcCtD
Epinephrine—Skin disorder—Lisinopril—systemic scleroderma	0.00111	0.00236	CcSEcCtD
Epinephrine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00111	0.00235	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.0011	0.00233	CcSEcCtD
Epinephrine—Nausea—Mometasone—systemic scleroderma	0.00109	0.00232	CcSEcCtD
Epinephrine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00231	CcSEcCtD
Epinephrine—Hyperglycaemia—Prednisone—systemic scleroderma	0.00108	0.00229	CcSEcCtD
Epinephrine—Dizziness—Captopril—systemic scleroderma	0.00107	0.00227	CcSEcCtD
Epinephrine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00226	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.00105	0.00223	CcSEcCtD
Epinephrine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00222	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisone—systemic scleroderma	0.00105	0.00222	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00221	CcSEcCtD
Epinephrine—Insomnia—Lisinopril—systemic scleroderma	0.00104	0.0022	CcSEcCtD
Epinephrine—Paraesthesia—Lisinopril—systemic scleroderma	0.00103	0.00218	CcSEcCtD
Epinephrine—Vomiting—Captopril—systemic scleroderma	0.00103	0.00218	CcSEcCtD
Epinephrine—Somnolence—Lisinopril—systemic scleroderma	0.00102	0.00216	CcSEcCtD
Epinephrine—SLC22A5—skin of body—systemic scleroderma	0.000995	0.0242	CbGeAlD
Epinephrine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000989	0.0021	CcSEcCtD
Epinephrine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000984	0.00209	CcSEcCtD
Epinephrine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00098	0.00208	CcSEcCtD
Epinephrine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000975	0.00207	CcSEcCtD
Epinephrine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00097	0.00206	CcSEcCtD
Epinephrine—Haemoglobin—Prednisone—systemic scleroderma	0.000963	0.00204	CcSEcCtD
Epinephrine—Nausea—Captopril—systemic scleroderma	0.000961	0.00204	CcSEcCtD
Epinephrine—Haemorrhage—Prednisone—systemic scleroderma	0.000958	0.00203	CcSEcCtD
Epinephrine—Hallucination—Prednisone—systemic scleroderma	0.000953	0.00202	CcSEcCtD
Epinephrine—Dizziness—Azathioprine—systemic scleroderma	0.000934	0.00198	CcSEcCtD
Epinephrine—ADRB1—lung—systemic scleroderma	0.000921	0.0224	CbGeAlD
Epinephrine—ADRA2A—connective tissue—systemic scleroderma	0.000918	0.0223	CbGeAlD
Epinephrine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000908	0.00193	CcSEcCtD
Epinephrine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000901	0.00191	CcSEcCtD
Epinephrine—Vomiting—Azathioprine—systemic scleroderma	0.000898	0.00191	CcSEcCtD
Epinephrine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000892	0.0019	CcSEcCtD
Epinephrine—Drowsiness—Methotrexate—systemic scleroderma	0.000892	0.00189	CcSEcCtD
Epinephrine—Flushing—Prednisone—systemic scleroderma	0.000889	0.00189	CcSEcCtD
Epinephrine—Dizziness—Leflunomide—systemic scleroderma	0.000882	0.00187	CcSEcCtD
Epinephrine—Renal failure—Methotrexate—systemic scleroderma	0.000876	0.00186	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000867	0.00184	CcSEcCtD
Epinephrine—Arrhythmia—Prednisone—systemic scleroderma	0.000856	0.00182	CcSEcCtD
Epinephrine—Sweating—Methotrexate—systemic scleroderma	0.000855	0.00182	CcSEcCtD
Epinephrine—Vomiting—Leflunomide—systemic scleroderma	0.000848	0.0018	CcSEcCtD
Epinephrine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000841	0.00179	CcSEcCtD
Epinephrine—Mental disorder—Prednisone—systemic scleroderma	0.000839	0.00178	CcSEcCtD
Epinephrine—Nausea—Azathioprine—systemic scleroderma	0.000839	0.00178	CcSEcCtD
Epinephrine—Erythema—Prednisone—systemic scleroderma	0.000834	0.00177	CcSEcCtD
Epinephrine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000809	0.00172	CcSEcCtD
Epinephrine—Haemoglobin—Methotrexate—systemic scleroderma	0.000804	0.00171	CcSEcCtD
Epinephrine—Haemorrhage—Methotrexate—systemic scleroderma	0.0008	0.0017	CcSEcCtD
Epinephrine—SLC22A5—digestive system—systemic scleroderma	0.000796	0.0194	CbGeAlD
Epinephrine—Nausea—Leflunomide—systemic scleroderma	0.000792	0.00168	CcSEcCtD
Epinephrine—ADRA2C—tendon—systemic scleroderma	0.000791	0.0192	CbGeAlD
Epinephrine—Agitation—Prednisone—systemic scleroderma	0.000766	0.00163	CcSEcCtD
Epinephrine—Dizziness—Lisinopril—systemic scleroderma	0.000758	0.00161	CcSEcCtD
Epinephrine—SLC22A5—tendon—systemic scleroderma	0.000757	0.0184	CbGeAlD
Epinephrine—Nausea—Mycophenolic acid—systemic scleroderma	0.000756	0.0016	CcSEcCtD
Epinephrine—Vomiting—Lisinopril—systemic scleroderma	0.000728	0.00155	CcSEcCtD
Epinephrine—CYP1A2—digestive system—systemic scleroderma	0.000721	0.0175	CbGeAlD
Epinephrine—Hypertension—Prednisone—systemic scleroderma	0.00072	0.00153	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000705	0.0015	CcSEcCtD
Epinephrine—Mental disorder—Methotrexate—systemic scleroderma	0.000701	0.00149	CcSEcCtD
Epinephrine—Erythema—Methotrexate—systemic scleroderma	0.000697	0.00148	CcSEcCtD
Epinephrine—ADRA2C—lung—systemic scleroderma	0.000694	0.0169	CbGeAlD
Epinephrine—CYP2C9—digestive system—systemic scleroderma	0.000684	0.0166	CbGeAlD
Epinephrine—Nausea—Lisinopril—systemic scleroderma	0.000681	0.00145	CcSEcCtD
Epinephrine—Nervous system disorder—Prednisone—systemic scleroderma	0.000667	0.00142	CcSEcCtD
Epinephrine—SLC22A5—lung—systemic scleroderma	0.000665	0.0162	CbGeAlD
Epinephrine—Tachycardia—Prednisone—systemic scleroderma	0.000664	0.00141	CcSEcCtD
Epinephrine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000664	0.00141	CcSEcCtD
Epinephrine—Skin disorder—Prednisone—systemic scleroderma	0.000661	0.0014	CcSEcCtD
Epinephrine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000658	0.0014	CcSEcCtD
Epinephrine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000638	0.00136	CcSEcCtD
Epinephrine—ADRA2A—tendon—systemic scleroderma	0.000631	0.0153	CbGeAlD
Epinephrine—Insomnia—Prednisone—systemic scleroderma	0.000615	0.00131	CcSEcCtD
Epinephrine—Paraesthesia—Prednisone—systemic scleroderma	0.000611	0.0013	CcSEcCtD
Epinephrine—CYP1A2—lung—systemic scleroderma	0.000602	0.0146	CbGeAlD
Epinephrine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000596	0.00127	CcSEcCtD
Epinephrine—Chest pain—Methotrexate—systemic scleroderma	0.000593	0.00126	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000589	0.00125	CcSEcCtD
Epinephrine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000558	0.00118	CcSEcCtD
Epinephrine—ADRA2A—lung—systemic scleroderma	0.000554	0.0135	CbGeAlD
Epinephrine—Skin disorder—Methotrexate—systemic scleroderma	0.000552	0.00117	CcSEcCtD
Epinephrine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.00055	0.00117	CcSEcCtD
Epinephrine—CYP3A4—digestive system—systemic scleroderma	0.000522	0.0127	CbGeAlD
Epinephrine—Insomnia—Methotrexate—systemic scleroderma	0.000514	0.00109	CcSEcCtD
Epinephrine—Paraesthesia—Methotrexate—systemic scleroderma	0.000511	0.00108	CcSEcCtD
Epinephrine—Somnolence—Methotrexate—systemic scleroderma	0.000506	0.00107	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000491	0.00104	CcSEcCtD
Epinephrine—Dizziness—Prednisone—systemic scleroderma	0.00045	0.000956	CcSEcCtD
Epinephrine—Vomiting—Prednisone—systemic scleroderma	0.000433	0.000919	CcSEcCtD
Epinephrine—Nausea—Prednisone—systemic scleroderma	0.000404	0.000858	CcSEcCtD
Epinephrine—Dizziness—Methotrexate—systemic scleroderma	0.000376	0.000799	CcSEcCtD
Epinephrine—Vomiting—Methotrexate—systemic scleroderma	0.000362	0.000768	CcSEcCtD
Epinephrine—Nausea—Methotrexate—systemic scleroderma	0.000338	0.000717	CcSEcCtD
Epinephrine—PAH—Metabolism—CTGF—systemic scleroderma	0.000292	0.0016	CbGpPWpGaD
Epinephrine—TNF—Spinal Cord Injury—MMP9—systemic scleroderma	0.000291	0.00159	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—IRF8—systemic scleroderma	0.000289	0.00158	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CD247—systemic scleroderma	0.000289	0.00158	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—ITGAM—systemic scleroderma	0.000289	0.00158	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—RHOB—systemic scleroderma	0.000284	0.00156	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—CSK—systemic scleroderma	0.000284	0.00156	CbGpPWpGaD
Epinephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000283	0.00155	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—SMAD7—systemic scleroderma	0.000282	0.00155	CbGpPWpGaD
Epinephrine—ADRA1A—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000281	0.00154	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—CSK—systemic scleroderma	0.000277	0.00152	CbGpPWpGaD
Epinephrine—TNF—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.00027	0.00148	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—TNFAIP3—systemic scleroderma	0.00027	0.00148	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—BLK—systemic scleroderma	0.000267	0.00147	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—CD247—systemic scleroderma	0.000267	0.00146	CbGpPWpGaD
Epinephrine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000265	0.00145	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—ITGAM—systemic scleroderma	0.00026	0.00143	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—CSK—systemic scleroderma	0.000258	0.00142	CbGpPWpGaD
Epinephrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000252	0.00138	CbGpPWpGaD
Epinephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000251	0.00138	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—SELP—systemic scleroderma	0.000247	0.00135	CbGpPWpGaD
Epinephrine—TNF—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000247	0.00135	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—ITGAM—systemic scleroderma	0.000243	0.00133	CbGpPWpGaD
Epinephrine—TNF—Spinal Cord Injury—TGFB1—systemic scleroderma	0.00024	0.00131	CbGpPWpGaD
Epinephrine—TNF—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000232	0.00127	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—RHOB—systemic scleroderma	0.00023	0.00126	CbGpPWpGaD
Epinephrine—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00023	0.00126	CbGpPWpGaD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000229	0.00126	CbGpPWpGaD
Epinephrine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000228	0.00125	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—SMAD7—systemic scleroderma	0.000226	0.00124	CbGpPWpGaD
Epinephrine—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000225	0.00123	CbGpPWpGaD
Epinephrine—TNF—Adipogenesis—TGFB1—systemic scleroderma	0.000222	0.00122	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CTLA4—systemic scleroderma	0.000219	0.0012	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—RHOB—systemic scleroderma	0.000218	0.0012	CbGpPWpGaD
Epinephrine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000213	0.00117	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR downstream signaling—RHOB—systemic scleroderma	0.000213	0.00117	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—CSK—systemic scleroderma	0.00021	0.00115	CbGpPWpGaD
Epinephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000209	0.00115	CbGpPWpGaD
Epinephrine—ADRBK1—GPCR downstream signaling—EDN1—systemic scleroderma	0.000208	0.00114	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—HSPG2—systemic scleroderma	0.000206	0.00113	CbGpPWpGaD
Epinephrine—ADRB3—GPCR ligand binding—CCL2—systemic scleroderma	0.000202	0.00111	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—CSK—systemic scleroderma	0.000199	0.00109	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—ITGAM—systemic scleroderma	0.000197	0.00108	CbGpPWpGaD
Epinephrine—ADRB1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000194	0.00106	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—RHOB—systemic scleroderma	0.000193	0.00106	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR ligand binding—EDN1—systemic scleroderma	0.000192	0.00105	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR downstream signaling—RHOB—systemic scleroderma	0.000192	0.00105	CbGpPWpGaD
Epinephrine—ADRB2—GPCR downstream signaling—RHOB—systemic scleroderma	0.000189	0.00104	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—EDN1—systemic scleroderma	0.000188	0.00103	CbGpPWpGaD
Epinephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000186	0.00102	CbGpPWpGaD
Epinephrine—TNF—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000181	0.000991	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—HLA-DQB1—systemic scleroderma	0.00018	0.000988	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—RHOB—systemic scleroderma	0.000179	0.000983	CbGpPWpGaD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000178	0.000977	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—RHOB—systemic scleroderma	0.000176	0.000968	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—RHOB—systemic scleroderma	0.000176	0.000965	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—RHOB—systemic scleroderma	0.000175	0.00096	CbGpPWpGaD
Epinephrine—ADRB1—GPCR ligand binding—EDN1—systemic scleroderma	0.000175	0.00096	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—RHOB—systemic scleroderma	0.000174	0.000956	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR ligand binding—EDN1—systemic scleroderma	0.000173	0.000951	CbGpPWpGaD
Epinephrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000173	0.000948	CbGpPWpGaD
Epinephrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000172	0.000946	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—RHOB—systemic scleroderma	0.000172	0.000944	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—IL1A—systemic scleroderma	0.000171	0.000939	CbGpPWpGaD
Epinephrine—ADRB2—GPCR ligand binding—EDN1—systemic scleroderma	0.000171	0.000939	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CD40LG—systemic scleroderma	0.00017	0.000934	CbGpPWpGaD
Epinephrine—ADRB3—GPCR downstream signaling—EDN1—systemic scleroderma	0.000167	0.000914	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—HSPG2—systemic scleroderma	0.000165	0.000905	CbGpPWpGaD
Epinephrine—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000163	0.000894	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—RHOB—systemic scleroderma	0.000163	0.000893	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR ligand binding—EDN1—systemic scleroderma	0.000162	0.000888	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—RHOB—systemic scleroderma	0.00016	0.000879	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—CSK—systemic scleroderma	0.000159	0.000874	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR ligand binding—EDN1—systemic scleroderma	0.000159	0.000874	CbGpPWpGaD
Epinephrine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000157	0.000862	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—RHOB—systemic scleroderma	0.000157	0.00086	CbGpPWpGaD
Epinephrine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000156	0.000854	CbGpPWpGaD
Epinephrine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000154	0.000843	CbGpPWpGaD
Epinephrine—PAH—Disease—NOS3—systemic scleroderma	0.000152	0.000834	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—EDN1—systemic scleroderma	0.000151	0.00083	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—SMAD7—systemic scleroderma	0.000147	0.000808	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—RHOB—systemic scleroderma	0.000146	0.000799	CbGpPWpGaD
Epinephrine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000145	0.000797	CbGpPWpGaD
Epinephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000143	0.000785	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—RHOB—systemic scleroderma	0.000142	0.000781	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR ligand binding—EDN1—systemic scleroderma	0.000142	0.000777	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—SMAD7—systemic scleroderma	0.000134	0.000737	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—SMAD7—systemic scleroderma	0.000133	0.00073	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—RHOB—systemic scleroderma	0.000132	0.000725	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR ligand binding—EDN1—systemic scleroderma	0.000132	0.000722	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—SMAD7—systemic scleroderma	0.000131	0.000721	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR ligand binding—CCL2—systemic scleroderma	0.000131	0.00072	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—MMP1—systemic scleroderma	0.00013	0.000715	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—CCL2—systemic scleroderma	0.000129	0.000707	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000128	0.000701	CbGpPWpGaD
Epinephrine—PAH—Metabolism—NOS3—systemic scleroderma	0.000127	0.000698	CbGpPWpGaD
Epinephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000127	0.000697	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SMAD7—systemic scleroderma	0.000124	0.000682	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—MMP2—systemic scleroderma	0.000123	0.000675	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SMAD7—systemic scleroderma	0.000122	0.000671	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—MMP1—systemic scleroderma	0.000122	0.000668	CbGpPWpGaD
Epinephrine—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	0.000121	0.000665	CbGpPWpGaD
Epinephrine—ADRB1—GPCR ligand binding—CCL2—systemic scleroderma	0.00012	0.000656	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR ligand binding—CCL2—systemic scleroderma	0.000119	0.00065	CbGpPWpGaD
Epinephrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000118	0.000648	CbGpPWpGaD
Epinephrine—ADRB2—GPCR ligand binding—CCL2—systemic scleroderma	0.000117	0.000642	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—RHOB—systemic scleroderma	0.000114	0.000625	CbGpPWpGaD
Epinephrine—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	0.000113	0.000621	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—HSPG2—systemic scleroderma	0.000112	0.000612	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—EDN1—systemic scleroderma	0.000111	0.000611	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR ligand binding—CCL2—systemic scleroderma	0.000111	0.000607	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000109	0.000599	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR ligand binding—CCL2—systemic scleroderma	0.000109	0.000598	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SMAD7—systemic scleroderma	0.000109	0.000596	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR downstream signaling—EDN1—systemic scleroderma	0.000109	0.000595	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—HSPG2—systemic scleroderma	0.000108	0.000595	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—HSPG2—systemic scleroderma	0.000108	0.00059	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—HSPG2—systemic scleroderma	0.000104	0.00057	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—RHOB—systemic scleroderma	0.000104	0.00057	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CSK—systemic scleroderma	0.000104	0.00057	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—CCL2—systemic scleroderma	0.000103	0.000567	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—RHOB—systemic scleroderma	0.000103	0.000565	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—RHOB—systemic scleroderma	0.000102	0.000557	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SMAD7—systemic scleroderma	0.000101	0.000554	CbGpPWpGaD
Epinephrine—PAH—Disease—TGFB1—systemic scleroderma	0.000101	0.000551	CbGpPWpGaD
Epinephrine—ADRB1—GPCR downstream signaling—EDN1—systemic scleroderma	9.89e-05	0.000542	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—MMP1—systemic scleroderma	9.89e-05	0.000542	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—EDN1—systemic scleroderma	9.86e-05	0.000541	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR downstream signaling—EDN1—systemic scleroderma	9.8e-05	0.000537	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—HSPG2—systemic scleroderma	9.8e-05	0.000537	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—HSPG2—systemic scleroderma	9.71e-05	0.000532	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—NOS3—systemic scleroderma	9.69e-05	0.000531	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.68e-05	0.000531	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR ligand binding—CCL2—systemic scleroderma	9.68e-05	0.000531	CbGpPWpGaD
Epinephrine—ADRB2—GPCR downstream signaling—EDN1—systemic scleroderma	9.67e-05	0.000531	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—RHOB—systemic scleroderma	9.62e-05	0.000527	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—HSPG2—systemic scleroderma	9.58e-05	0.000526	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—RHOB—systemic scleroderma	9.46e-05	0.000519	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CSK—systemic scleroderma	9.46e-05	0.000519	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—NOS3—systemic scleroderma	9.45e-05	0.000518	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CSK—systemic scleroderma	9.38e-05	0.000514	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CSK—systemic scleroderma	9.26e-05	0.000508	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—MMP9—systemic scleroderma	9.25e-05	0.000507	CbGpPWpGaD
Epinephrine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	9.19e-05	0.000504	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—EDN1—systemic scleroderma	9.15e-05	0.000502	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—HSPG2—systemic scleroderma	9.07e-05	0.000497	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—EDN1—systemic scleroderma	9.01e-05	0.000494	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR ligand binding—CCL2—systemic scleroderma	8.99e-05	0.000493	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—EDN1—systemic scleroderma	8.98e-05	0.000493	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—EDN1—systemic scleroderma	8.94e-05	0.00049	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—IL1B—systemic scleroderma	8.93e-05	0.00049	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—HSPG2—systemic scleroderma	8.93e-05	0.00049	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—EDN1—systemic scleroderma	8.9e-05	0.000488	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—NOS3—systemic scleroderma	8.82e-05	0.000484	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—HSPG2—systemic scleroderma	8.81e-05	0.000483	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—EDN1—systemic scleroderma	8.78e-05	0.000482	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CSK—systemic scleroderma	8.76e-05	0.00048	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CSK—systemic scleroderma	8.62e-05	0.000473	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—CTGF—systemic scleroderma	8.45e-05	0.000463	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—RHOB—systemic scleroderma	8.41e-05	0.000461	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—EDN1—systemic scleroderma	8.31e-05	0.000456	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	8.28e-05	0.000454	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—CTGF—systemic scleroderma	8.22e-05	0.000451	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—EDN1—systemic scleroderma	8.18e-05	0.000449	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—EDN1—systemic scleroderma	8e-05	0.000439	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—HSPG2—systemic scleroderma	7.93e-05	0.000435	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—CTGF—systemic scleroderma	7.88e-05	0.000432	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—RHOB—systemic scleroderma	7.81e-05	0.000428	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CSK—systemic scleroderma	7.66e-05	0.00042	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—TGFB1—systemic scleroderma	7.62e-05	0.000418	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—CCL2—systemic scleroderma	7.61e-05	0.000417	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—EDN1—systemic scleroderma	7.43e-05	0.000408	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—HSPG2—systemic scleroderma	7.37e-05	0.000404	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—EDN1—systemic scleroderma	7.27e-05	0.000399	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—NOS3—systemic scleroderma	7.17e-05	0.000393	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CSK—systemic scleroderma	7.11e-05	0.00039	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—NOS3—systemic scleroderma	6.78e-05	0.000372	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—EDN1—systemic scleroderma	6.75e-05	0.00037	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—CCL2—systemic scleroderma	6.74e-05	0.00037	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—CTGF—systemic scleroderma	6.68e-05	0.000366	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—TGFB1—systemic scleroderma	6.4e-05	0.000351	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—TGFB1—systemic scleroderma	6.25e-05	0.000343	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—CCL2—systemic scleroderma	6.14e-05	0.000337	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—CCL2—systemic scleroderma	6.11e-05	0.000335	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—CCL2—systemic scleroderma	6.08e-05	0.000334	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—CCL2—systemic scleroderma	6e-05	0.000329	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—TGFB1—systemic scleroderma	5.83e-05	0.00032	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—EDN1—systemic scleroderma	5.82e-05	0.000319	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—HSPG2—systemic scleroderma	5.69e-05	0.000312	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—CCL2—systemic scleroderma	5.68e-05	0.000312	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—CCL2—systemic scleroderma	5.59e-05	0.000307	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—NOS3—systemic scleroderma	5.45e-05	0.000299	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—MMP9—systemic scleroderma	5.44e-05	0.000298	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EDN1—systemic scleroderma	5.3e-05	0.000291	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EDN1—systemic scleroderma	5.26e-05	0.000288	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EDN1—systemic scleroderma	5.19e-05	0.000285	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—CCL2—systemic scleroderma	4.97e-05	0.000272	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EDN1—systemic scleroderma	4.91e-05	0.000269	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—HSPG2—systemic scleroderma	4.86e-05	0.000267	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EDN1—systemic scleroderma	4.83e-05	0.000265	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—TGFB1—systemic scleroderma	4.74e-05	0.00026	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—CCL2—systemic scleroderma	4.61e-05	0.000253	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—TGFB1—systemic scleroderma	4.49e-05	0.000246	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—MMP9—systemic scleroderma	4.37e-05	0.00024	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CTGF—systemic scleroderma	4.31e-05	0.000237	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EDN1—systemic scleroderma	4.29e-05	0.000235	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EDN1—systemic scleroderma	3.99e-05	0.000219	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CCL2—systemic scleroderma	3.98e-05	0.000218	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—HSPG2—systemic scleroderma	3.75e-05	0.000206	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CTGF—systemic scleroderma	3.69e-05	0.000202	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—NOS3—systemic scleroderma	3.68e-05	0.000202	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CCL2—systemic scleroderma	3.63e-05	0.000199	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—TGFB1—systemic scleroderma	3.6e-05	0.000197	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CCL2—systemic scleroderma	3.59e-05	0.000197	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—NOS3—systemic scleroderma	3.58e-05	0.000196	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—NOS3—systemic scleroderma	3.55e-05	0.000195	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CCL2—systemic scleroderma	3.55e-05	0.000195	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—NOS3—systemic scleroderma	3.43e-05	0.000188	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CCL2—systemic scleroderma	3.36e-05	0.000184	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CCL2—systemic scleroderma	3.3e-05	0.000181	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—NOS3—systemic scleroderma	3.23e-05	0.000177	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—NOS3—systemic scleroderma	3.2e-05	0.000176	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—NOS3—systemic scleroderma	3.16e-05	0.000173	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—NOS3—systemic scleroderma	2.99e-05	0.000164	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—NOS3—systemic scleroderma	2.94e-05	0.000161	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CCL2—systemic scleroderma	2.93e-05	0.000161	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—NOS3—systemic scleroderma	2.91e-05	0.000159	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MMP9—systemic scleroderma	2.85e-05	0.000156	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.84e-05	0.000156	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CCL2—systemic scleroderma	2.73e-05	0.00015	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—NOS3—systemic scleroderma	2.62e-05	0.000143	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MMP9—systemic scleroderma	2.59e-05	0.000142	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MMP9—systemic scleroderma	2.57e-05	0.000141	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MMP9—systemic scleroderma	2.54e-05	0.000139	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NOS3—systemic scleroderma	2.43e-05	0.000133	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MMP9—systemic scleroderma	2.4e-05	0.000132	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MMP9—systemic scleroderma	2.36e-05	0.00013	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TGFB1—systemic scleroderma	2.35e-05	0.000129	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TGFB1—systemic scleroderma	2.14e-05	0.000117	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TGFB1—systemic scleroderma	2.12e-05	0.000116	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MMP9—systemic scleroderma	2.1e-05	0.000115	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TGFB1—systemic scleroderma	2.09e-05	0.000115	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TGFB1—systemic scleroderma	1.98e-05	0.000108	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MMP9—systemic scleroderma	1.95e-05	0.000107	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TGFB1—systemic scleroderma	1.95e-05	0.000107	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.88e-05	0.000103	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TGFB1—systemic scleroderma	1.73e-05	9.48e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TGFB1—systemic scleroderma	1.61e-05	8.81e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—NOS3—systemic scleroderma	1.6e-05	8.8e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.24e-05	6.79e-05	CbGpPWpGaD
